{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:54:04Z","timestamp":1791262444454,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM). Although several insulin resistance (IR)-related indices have been proposed as surrogate markers, their comparative performance and the influence of diabetes duration remain unclear. We compared the associations of eight IR-related indices with MAFLD and evaluated the modifying effect of diabetes duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cross-sectional study included 5,996 patients with T2DM, of whom 3,087 had MAFLD. Logistic regression was used to evaluate the associations of eight IR-related indices (TyG, TyG-BMI, METS-IR, CHG, CTI, HOMA-IR, SHR, and AIP) with prevalent MAFLD. To facilitate comparison across indices measured on different scales, odds ratios (ORs) were additionally estimated per 1-standard deviation (SD) increase. Receiver operating characteristic (ROC) curve analysis was used to assess discriminative performance. LASSO regression was used for covariate selection, followed by multivariable logistic regression, restricted cubic spline (RCS) analysis, and interaction analysis. Internal validation of the multivariable model was performed using 1,000 bootstrap resamples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All eight IR-related indices were significantly associated with prevalent MAFLD. After standardization, AIP showed the largest association estimate per 1-SD increase (OR\u00a0=\u00a02.137, 95% CI: 2.007\u20132.275). AIP also showed the highest, although moderate, discriminative performance among the eight indices (AUC\u00a0=\u00a00.692). After LASSO-based covariate selection and multivariable adjustment, AIP remained independently associated with prevalent MAFLD (OR\u00a0=\u00a04.968, 95% CI: 4.100\u20136.035). Adjusted RCS analysis indicated a nonlinear association between AIP and prevalent MAFLD (P for overall &amp;lt; 0.001; P for nonlinearity = 0.040). The revised multivariable model had an apparent AUC of 0.758 (95% CI: 0.746\u20130.771), with an optimism-corrected AUC of 0.756 after bootstrap internal validation. Significant interactions were observed between AIP and diabetes duration when duration was modeled continuously (P for interaction = 0.031) and categorically (&amp;lt;5 vs. \u22655 years; P for interaction = 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among the eight IR-related indices evaluated, AIP showed the largest standardized association with prevalent MAFLD and the highest discriminative performance in patients with T2DM. The association between AIP and MAFLD may vary according to diabetes duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1952511","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:56Z","timestamp":1791260756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes duration modifies the association between AIP and MAFLD in type 2 diabetes"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiayu","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Affiliated Dongyang Hospital of Wenzhou Medical University","place":["Dongyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokang","family":"Hu","sequence":"additional","affiliation":[{"name":"Vascular Signalling, Molecular Cardiology, Department of Cardiology I-Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Liang","sequence":"additional","affiliation":[{"name":"Vascular Signalling, Molecular Cardiology, Department of Cardiology I-Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital M\u00fcnster","place":["M\u00fcnster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangtao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Dongyang Hospital of Wenzhou Medical University","place":["Dongyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13679-025-00673-5","article-title":"Beyond discrete diagnoses: conceptualizing obesity-associated metabolic disorders as a unified, dynamic continuum","volume":"14","author":"Xie","year":"2025","journal-title":"Curr Obes Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study","volume":"384","author":"Kim","year":"2024","journal-title":"BMJ (Clinical Res ed)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr Obes Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/nu14234969","article-title":"The diagnostic and prognostic value of the triglyceride-glucose index in metabolic dysfunction-associated fatty liver disease (MAFLD): a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Nutrients"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1770104","article-title":"A novel glucose-lipid metabolism-related indicator and its association with metabolic dysfunction-associated fatty liver disease: a cross-sectional study based on a health check-up population","volume":"17","author":"Tang","year":"2026","journal-title":"Front Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-026-03119-x","article-title":"Association of the C-reactive protein-triglyceride-glucose index with metabolic dysfunction-associated steatotic liver disease and long-term all-cause and cardiovascular mortality: evidence from two nationwide prospective cohort studies","volume":"25","author":"Jin","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-025-02546-1","article-title":"AIP, fatty liver, and HbA1c as modifiers of the C-index and diabetes risk relationship","volume":"24","author":"Liu","year":"2025","journal-title":"Lipids Health Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12872-025-05409-w","article-title":"Association between atherogenic index of plasma and various metabolic conditions: an umbrella review on meta-analyses","volume":"26","author":"Rashidian","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1800577","article-title":"Association between the atherogenic index of plasma and metabolic-associated\/nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"17","author":"Zhao","year":"2026","journal-title":"Front Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S331948","article-title":"Impact of the 2020 China Diabetes Society Guideline on the prevalence of diabetes mellitus and eligibility for antidiabetic treatment in China","volume":"14","author":"Shi","year":"2021","journal-title":"Int J Gen Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.08.026","article-title":"Triglyceride glucose (TyG) index: a promising biomarker for diagnosis and treatment of different diseases","volume":"131","author":"Sun","year":"2024","journal-title":"Eur J Internal Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149731","article-title":"Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals","volume":"11","author":"Er","year":"2016","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0883","article-title":"METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes","volume":"178","author":"Bello-Chavolla","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14343","article-title":"A novel index for diagnosis of type 2 diabetes mellitus: cholesterol, high density lipoprotein, and glucose (CHG) index","volume":"16","author":"Mansoori","year":"2024","journal-title":"J Diabetes Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.905266","article-title":"A novel inflammation and insulin resistance related indicator to predict the survival of patients with cancer","volume":"13","author":"Ruan","year":"2022","journal-title":"Front Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/bf00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2660","article-title":"Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio","volume":"100","author":"Roberts","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01073-0","article-title":"The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy","volume":"46","author":"Dobi\u00e1sov\u00e1","year":"2000","journal-title":"Vnitrni Lekarstvi"},{"key":"B22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin Sci (London Engl 1979)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092101","article-title":"Atherogenic index of plasma in non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"10","author":"Ismaiel","year":"2022","journal-title":"Biomedicines"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4093\/dmj.2021.0280","article-title":"Insulin resistance: from mechanisms to therapeutic strategies","volume":"46","author":"Lee","year":"2021","journal-title":"Diabetes Metab J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06499-z","article-title":"The role of the beta cell in type 2 diabetes: new findings from the last 5 years","volume":"68","author":"Yau","year":"2025","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70014","article-title":"Overview of oxidative stress and inflammation in diabetes","volume":"16","author":"Weinberg Sibony","year":"2024","journal-title":"J Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01114-y","article-title":"Insulin resistance in type 2 diabetes mellitus","volume":"21","author":"Accili","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3952-1","article-title":"Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions","volume":"59","author":"Cusi","year":"2016","journal-title":"Diabetologia"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1952511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:57Z","timestamp":1791260757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1952511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":29,"alternative-id":["10.3389\/fendo.2026.1952511"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1952511","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1952511"}}